- Home
- UNCY vs YI Comparison
UNCY vs YI Comparison
Compare UNCY & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- YI
- Stock Information
- Founded
- UNCY 2016
- YI 2010
- Country
- UNCY United States
- YI China
- Employees
- UNCY 22
- YI N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- UNCY Health Care
- YI Consumer Staples
- Exchange
- UNCY Nasdaq
- YI Nasdaq
- Market Cap
- UNCY 71.3M
- YI 70.0M
- IPO Year
- UNCY 2021
- YI N/A
- Fundamental
- Price
- UNCY $0.61
- YI $8.01
- Analyst Decision
- UNCY Strong Buy
- YI
- Analyst Count
- UNCY 4
- YI 0
- Target Price
- UNCY $6.38
- YI N/A
- AVG Volume (30 Days)
- UNCY 889.6K
- YI 12.9K
- Earning Date
- UNCY 05-14-2025
- YI 06-10-2025
- Dividend Yield
- UNCY N/A
- YI N/A
- EPS Growth
- UNCY N/A
- YI N/A
- EPS
- UNCY N/A
- YI N/A
- Revenue
- UNCY N/A
- YI $1,973,017,082.00
- Revenue This Year
- UNCY N/A
- YI N/A
- Revenue Next Year
- UNCY $1,422.24
- YI N/A
- P/E Ratio
- UNCY N/A
- YI N/A
- Revenue Growth
- UNCY N/A
- YI N/A
- 52 Week Low
- UNCY $0.20
- YI $4.15
- 52 Week High
- UNCY $0.96
- YI $13.00
- Technical
- Relative Strength Index (RSI)
- UNCY 49.67
- YI 54.03
- Support Level
- UNCY $0.56
- YI $7.54
- Resistance Level
- UNCY $0.62
- YI $8.25
- Average True Range (ATR)
- UNCY 0.05
- YI 0.32
- MACD
- UNCY 0.00
- YI 0.04
- Stochastic Oscillator
- UNCY 74.83
- YI 65.63
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.